Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Stomach Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 2Adenocarcinoma 2Radioactive Iodine-refractory Differentiated Thyroid Cancer 1Radiation Pneumonitis 1Pancreatic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Biliary Tract Carcinoma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 4Oxaliplatin 4zolbetuximab 2camrelizumab 2apatinib 2S 1 (combination) 2Paclitaxel 2Nivolumab 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tislelizumab 1tepotinib 1relugolix 1regorafenib 1lenvatinib 1durvalumab 1dabrafenib 1cemiplimab 1cabazitaxel 1alpha-2'-deoxythioguanosine 1X-Rays 1Vinorelbine 1Trifluridine 1Surveys and Questionnaires 1Ramucirumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Radiation 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma × apatinib × Clear all
NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Ruijin Hospital

Phase 2 Active not recruiting
80 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Ruijin Hospital

Phase 2/3 Active not recruiting
580 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡